Madrigal Pharmaceuticals (MDGL)
Healthcare · Biotechnology
1 member of Congress has disclosed 1 trade in Madrigal Pharmaceuticals (MDGL) since 2023: 0 buys and 1 sale. The most recent was disclosed on May 19, 2023.
- Trades disclosed
- 1
- Members trading
- 1
- Buys / sells
- 0 / 1
- Reported value
- $1K–$15K
Keep following the company.
Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.
What else is happening at MDGL
All research →Company filings and public records connected to this stock, ordered by when they became public or were first observed.
MDGL: BAKER BROS. ADVISORS LP; Baker Bros. Advisors (GP) LLC; BAKER FELIX; BAKER JULIAN; 667, L.P.; Baker Brothers Life Sciences LP reported buying shares
5 reported purchases of non-derivative securities. Code P includes open-market and private purchases; it does not establish motive.
Who traded MDGL
- Rep. Daniel S. Goldman (D-NY-10)0 buys · 1 sale01May 19, 2023
All trades
- May 19, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
Sold Madrigal Pharmaceuticals MDGL
$1K–$15K · Traded Apr 10, 2023 · disclosed May 19, 2023
From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.